1. Home
  2. MAIA vs KLXE Comparison

MAIA vs KLXE Comparison

Compare MAIA & KLXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • KLXE
  • Stock Information
  • Founded
  • MAIA 2018
  • KLXE 2018
  • Country
  • MAIA United States
  • KLXE United States
  • Employees
  • MAIA N/A
  • KLXE N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • KLXE Oilfield Services/Equipment
  • Sector
  • MAIA Health Care
  • KLXE Energy
  • Exchange
  • MAIA Nasdaq
  • KLXE Nasdaq
  • Market Cap
  • MAIA 46.7M
  • KLXE 35.8M
  • IPO Year
  • MAIA 2022
  • KLXE N/A
  • Fundamental
  • Price
  • MAIA $1.94
  • KLXE $1.99
  • Analyst Decision
  • MAIA
  • KLXE Hold
  • Analyst Count
  • MAIA 0
  • KLXE 1
  • Target Price
  • MAIA N/A
  • KLXE $4.50
  • AVG Volume (30 Days)
  • MAIA 526.7K
  • KLXE 283.3K
  • Earning Date
  • MAIA 08-08-2025
  • KLXE 08-06-2025
  • Dividend Yield
  • MAIA N/A
  • KLXE N/A
  • EPS Growth
  • MAIA N/A
  • KLXE N/A
  • EPS
  • MAIA N/A
  • KLXE N/A
  • Revenue
  • MAIA N/A
  • KLXE $688,600,000.00
  • Revenue This Year
  • MAIA N/A
  • KLXE N/A
  • Revenue Next Year
  • MAIA N/A
  • KLXE $3.97
  • P/E Ratio
  • MAIA N/A
  • KLXE N/A
  • Revenue Growth
  • MAIA N/A
  • KLXE N/A
  • 52 Week Low
  • MAIA $1.40
  • KLXE $1.51
  • 52 Week High
  • MAIA $4.24
  • KLXE $7.66
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 61.28
  • KLXE 43.11
  • Support Level
  • MAIA $1.60
  • KLXE $1.85
  • Resistance Level
  • MAIA $1.95
  • KLXE $2.06
  • Average True Range (ATR)
  • MAIA 0.11
  • KLXE 0.30
  • MACD
  • MAIA 0.02
  • KLXE -0.06
  • Stochastic Oscillator
  • MAIA 94.39
  • KLXE 1.74

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About KLXE KLX Energy Services Holdings Inc.

KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.

Share on Social Networks: